The European Committee for Treatment and Research in MS (ECTRIMS) annual meeting presented new data that helped to clarify the mode of action of anti-CD20 agents and address some safety issues that have arisen during the COVID-19 pandemic. Read More
Neurology
ECTRIMS 2021 SLIDE DECK
October 22, 2021Selected highlights from ECTRIMS 2021
Virtual Congress – 13-15 October 2021
52 slides
Scientific review:
Dr. Daniel Selchen, Senior Consultant, BARLO MS centre, St. Michael’s Hospital, Toronto, Canada
Read More
How prognostic is NEDA?
October 20, 2021A new study has found that a high proportion of MS patients with no evidence of disease activity (NEDA) in the first two years of treatment will experience relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA) (Prosperini et al. Neurol Neuroimmunol Neuroinflamm 2021;8:e1059). Read More
ECTRIMS 2021 HIGHLIGHTS – FRIDAY, OCTOBER 15 EDITION
October 15, 202137th Congress of the European Committee for Treatment and Research in Multiple Sclerosis – October 13-15, 2021
The following summarizes some of the highlights from Day 3 of ECTRIMS 2021.
ECTRIMS 2021 POSTER PICKS – DAY 3
October 15, 202137th Congress of the European Committee for Treatment and Research in Multiple Sclerosis – October 13-15, 2021 Read More